M A Mandelkern
Overview
Explore the profile of M A Mandelkern including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
816
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Okita K, Morales A, Dean A, Johnson M, Lu V, Farahi J, et al.
Mol Psychiatry
. 2017 Sep;
23(5):1320-1327.
PMID: 28894300
Chronic methamphetamine use poses potentially devastating consequences for directly affected individuals and for society. Lower dopamine D2-type receptor availability has been observed in striata of methamphetamine users as compared with...
2.
Kohno M, Okita K, Morales A, Robertson C, Dean A, Ghahremani D, et al.
Mol Psychiatry
. 2016 Feb;
21(11):1554-1560.
PMID: 26830141
Stimulant use disorders are associated with deficits in striatal dopamine receptor availability, abnormalities in mesocorticolimbic resting-state functional connectivity (RSFC) and impulsivity. In methamphetamine-dependent research participants, impulsivity is correlated negatively with...
3.
Morales A, Kohno M, Robertson C, Dean A, Mandelkern M, London E
Mol Psychiatry
. 2015 May;
20(6):658.
PMID: 25993553
No abstract available.
4.
Morales A, Kohno M, Robertson C, Dean A, Mandelkern M, London E
Mol Psychiatry
. 2015 Apr;
20(6):764-71.
PMID: 25896164
Dysfunction of the mesocorticolimbic system has a critical role in clinical features of addiction. Despite evidence suggesting that midbrain dopamine receptors influence amphetamine-induced dopamine release and that dopamine is involved...
5.
Ishibashi K, Berman S, Paz-Filho G, Lee B, Robertson C, Mandelkern M, et al.
Mol Psychiatry
. 2011 Nov;
17(4):352-3.
PMID: 22105625
No abstract available.
6.
Zorick T, Lee B, Mandelkern M, Fong T, Robertson C, Ghahremani D, et al.
Mol Psychiatry
. 2011 Oct;
17(6):569-71.
PMID: 22024765
No abstract available.
7.
Jarcho J, Chang L, Berman M, Suyenobu B, Naliboff B, Lieberman M, et al.
Aliment Pharmacol Ther
. 2008 Dec;
28(3):344-52.
PMID: 19086332
Background: Symptom improvement in irritable bowel syndrome (IBS) treatment trials varies widely, with only 50-70% of patients qualifying as responders. Factors predicting treatment responsiveness are not known, although we have...
8.
Saxena S, Gorbis E, ONeill J, Baker S, Mandelkern M, Maidment K, et al.
Mol Psychiatry
. 2008 Jan;
14(2):197-205.
PMID: 18180761
Brief intensive cognitive-behavioral therapy (CBT) using exposure and response prevention significantly improves obsessive-compulsive disorder (OCD) symptoms in as little as 4 weeks. However, it has been thought that much longer...
9.
Berman S, Voytek B, Mandelkern M, Hassid B, Isaacson A, Monterosso J, et al.
Mol Psychiatry
. 2007 Oct;
13(9):897-908.
PMID: 17938635
Changes in brain function during the initial weeks of abstinence from chronic methamphetamine abuse may substantially affect clinical outcome, but are not well understood. We used positron emission tomography with...
10.
Bauer M, London E, Rasgon N, Berman S, Frye M, Altshuler L, et al.
Mol Psychiatry
. 2005 Feb;
10(5):456-69.
PMID: 15724143
Supplementation of standard treatment with high-dose levothyroxine (L-T(4)) is a novel approach for treatment-refractory bipolar disorders. This study tested for effects on brain function associated with mood alterations in bipolar...